This week in the Innovation Partners BioBlog, we look at several top stories including the record-breaking FDA approval rate for generic drugs. Human leveled serious charges against several pharmaceutical firms including Teva for price fixing, alleging up to 1,000% overcharge on some drugs including those treating asthma and breast cancer. These and more are our ...

In this week’s Innovation Partners BioBlog, we look at several top stories from the pharmaceutical industry. Merck is testing machine learning to predict demand, a move that is expected to prevent wasteful stockpiling and expired drugs. Pfizer fills the gap left by Teva’s discontinuation of an important cancer-fighting drug often used for children’s cancers. Several ...

California Governor Newsom inked bill AB 824 and is expected to sign AB 744 this week, both of which will impact healthcare payment models. Companies seeking to manage healthcare costs are actively trying to influence where medications are delivered. New cancer research in triple negative breast cancer appears promising. Read on for these and other ...

The European Society of Medical Oncology (ESMO) conference wrapped up this week with many exciting announcements and developments. New studies from Lilly, AstraZeneca, Merck and others showed promise treating lung cancer, thyroid cancer, prostate cancer and more. Hospitals and medical groups are pushing back at the Trump administration’s focus on publishing payer-negotiated pricing. Read on ...

The Democrats unveiled their plan to combat rising drug prices. House Leader Nancy Pelosi’s plan would lift the ban on the HHS to allow the secretary to negotiate Medicare drug prices. Pharmaceutical companies would be forced to comply or face stiff penalties. Other top stories this week focus on the cost of pharmaceutical drugs and ...

In this week’s Innovation Partners’ BioBlog, states consider several models for value-based drug pricing but face significant challenges to move forward with any of them. A House panel is investigating the role that private equity firms may play in surprise patient billing; many of these firms own physician staffing companies, who are out of a ...

In this week’s Innovation Partners BioBlog, we feature several stories on the continuing healthcare debate. The President promises a new healthcare plan, but any plan promises to be contentious to some on either side of the aisle. New CPT codes were announced for 2020 that include e-visits and remote monitoring. Cigna launched a new befit ...

The Centers for Medicare and Medicaid Services launched a brand-new, redesigned site to help the 60 million eligible for Part D coverage and Medicare Advantage to comparison shop their plans. New research in cancer offers the potential for breakthroughs in non-small-cell lung cancer. MedCo’s new cholesterol-lowering drug might give Amgen and Sanofi a run for ...

In this week’s Innovation Partners BioBlog, we take a look at a new report from Accenture Life Sciences which indicates that patients prefer to turn to patient groups rather than pharmaceutical companies for resources and information. This may indicate a potential opportunity for pharmaceutical companies to explore. Several legal battles are in the spotlight, including ...

Tufts Health Plan and Harvard Pilgrim announced a planned merger, which would make the new as-yet-to-be-named organization a rising competitor to the Partners Health Group, a dominant player in the area. CMS will display the 5-star rating next to plans on the Affordable Care website, a move to make the data more visible to potential ...